MOLECULAR PARTNERS AG Stock Price, News & Analysis

Molecular Partners (SIX/NASDAQ: MOLN) formed a Scientific Advisory Board (SAB) for its radiopharmaceutical program, chaired by Prof. Ken Herrmann, M.D., to guide transition from early clinical validation to strategic development decisions.

The SAB includes James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D., and will advise on candidate development, platform expansion (additional isotopes and targeting), and clinical strategy. The company's lead Radio-DARPin MP0712 is a 212Pb-based DLL3-targeting candidate (co-developed with Orano Med) with first human images presented recently and plans for phase 1 initiation. A second program, MP0726, targets mesothelin for cancers including ovarian cancer. The release emphasizes Radio-DARPins as vectors to deliver alpha-emitting isotopes selectively to tumors.

Molecular Partners (NASDAQ: MOLN) presented updated Phase 1/2a data for tetra-specific T-cell engager MP0533 in relapsed/refractory AML at ASH on December 7, 2025. As of the September 1, 2025 cut-off, 54 patients received MP0533 and 8 of 48 evaluable patients responded (5 composite complete responses and 3 MLFS). Densified and higher-frequency dosing (cohorts 8–9) was tolerable, increased serum exposure in cycle 1, and showed preliminary antitumor activity. Responses clustered in patients with <20% bone marrow blasts at baseline. Cohort 10 is ongoing with data expected in 2026.

Molecular Partners (NASDAQ: MOLN) presented new human imaging and mechanism data for MP0712, a DLL3-targeting Radio-DARPin, at TRP Summit Europe on Nov 12, 2025. A named‑patient case from South Africa showed specific tumor uptake at 24 hours and sustained signal over 4 days using 203Pb imaging, with limited kidney and liver exposure. The company filed a Phase 1 IND for MP0712 and expects to initiate the US trial by end‑2025, with initial clinical data anticipated in 2026. Presentation and webcast details were provided for Nov 12, 2025.

Molecular Partners (NASDAQ: MOLN) will present additional preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation at SITC 2025 (Nov 5-9; poster Nov 7).

Preclinical results show the AND-gated Switch-DARPin selectively triggered T cell cytotoxicity only against cells co-expressing MSLN and EpCAM, improved T cell activation and proliferation with CD2/CD3 co-stimulation, and induced significant tumor regression in a xenograft model without systemic cytokine release, indicating a favorable safety signal.

Molecular Partners (NASDAQ: MOLN) will present updated Phase 1/2a data for MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), at the ASH Annual Meeting on December 7, 2025.

The poster summarizes first-in-human, multicenter, open-label results in relapsed/refractory AML and MDS/AML (ClinicalTrials.gov: NCT05673057). MP0533 showed an acceptable safety profile across dose ranges 1–9; densified dosing used in DR 8–9 appears tolerable and preliminary antitumor activity is described. The study is dosing in DR 10. Abstracts posted on the ASH website from 9:00 AM ET on November 3, 2025.

Molecular Partners (NASDAQ:MOLN / SIX:MOLN) filed an IND for MP0712 (212Pb DLL3 Radio-DARPin) with a Phase 1 start expected before year-end 2025 and first compassionate-care 203Pb images to be shown at the TRP Summit in November. Updated MP0533 Phase 1/2a data (AML) will be presented at ASH in December, with cohort 8 showing 3 of 8 evaluable responders and one patient >12 months on treatment.

Protocol approved for a Phase 2 investigator-initiated trial of MP0317 (FAP x CD40). Cash, equivalents and short-term deposits were CHF 105 million as of Sept 30, 2025, and the company expects runway until 2028. Full‑year 2025 operating expense guidance: CHF 55–60 million.

Molecular Partners (NASDAQ:MOLN) reported H1 2025 financial results and pipeline updates, highlighting progress in its clinical programs. The company's lead candidate MP0533 for AML/MDS showed promising results with >30% response rate in cohort 8, including durable responses. Their radio-DARPin program MP0712 is advancing toward Phase 1 trials, with IND filing expected by end of 2025.

The company appointed Martin Steegmaier, Ph.D. as CSO and announced a workforce reduction of up to 24%. With CHF 114 million in cash and deposits as of June 30, 2025, Molecular Partners has extended its runway into 2028. Expected operating expenses for 2025 are CHF 55-65 million.

Molecular Partners (NASDAQ:MOLN) has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the Executive Committee, effective October 1, 2025. Dr. Steegmaier brings extensive oncology drug development experience from his previous roles at SOTIO Biotech, MorphoSys, Roche, and Boehringer Ingelheim.

As CSO, Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. His background includes significant experience in developing antibody-based therapeutics in immuno-oncology and hematology-oncology.

Molecular Partners (NASDAQ: MOLN) and Orano Med announced preclinical data for MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, at SNMMI 2025. The data showed MP0726 demonstrates high affinity and selective binding to membrane-bound MSLN, with favorable biodistribution in tumor models showing up to 34% tumor accumulation at 24 hours post-injection and a tumor-to-kidney ratio of 4.5. This represents the company's second Radio-DARPin program, with the first program MP0712 (targeting DLL3) expected to begin Phase 1 trials in H2 2025. The collaboration leverages Orano Med's expertise in targeted alpha-particle therapies with 212Pb and Molecular Partners' DARPin technology to address the challenge of shed MSLN acting as a decoy receptor in cancer treatment.